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Abstract
Background: Autonomic imbalance is associated with poor prognosis of patients with systolic dys-
function. Most of the previous data were written several years ago and constituted to cardiovascular 
or arrhythmic mortality. The current treatment of these patients has improved substantially over the 
last decades, and thus, the population at risk of death may have altered as well. Consequently, data on 
high-risk patients with systolic dysfunction in the modern era are sparse and those from previous trials 
may no longer be applicable. The aim herein, was to verify whether well-known autonomic indices — 
baroreflex sensitivity (BRS) and heart rate variability (HRV) — remain accurate predictors of mortality 
in patients with systolic dysfunction. 
Methods: Non-invasively obtained BRS and HRV were analyzed in 205 clinically stable patients with 
left ventricular ejection fraction (LVEF) ≤ 40%. 28 patients died within 28 ± 9 month follow-up. 
Results: Baroreflex sensitivity, low-frequency (LF) in normalized units, LF to high-frequency ratio and 
standard deviation of average R-R intervals were significantly associated with mortality; cut-off values 
of the highest discriminatory power for abovementioned parameters were ≤ 3.0 ms/mmHg, ≤ 41, ≤ 0.7 
and ≤ 25 ms, respectively. In bivariate Cox analyses (adjusted for LVEF, New York Heart Association 
[NYHA] or absence of implantable cardioverter-defibrillator [ICD]) autonomic indices remain signifi-
cant predictors of death. 
Conclusions: Baroreflex sensitivity and HRV — may still be helpful in identifying patients with left 
ventricular systolic dysfunction at the highest risk of all-cause mortality, independently of LVEF, NYHA 
class, and ICD implantation. (Cardiol J XXXX; XX, X: xx–xx)
Key words: baroreflex sensitivity, heart rate variability, all-cause mortality,  
left ventricular dysfunction
Introduction
Heart failure (HF) is a constantly growing 
global pandemic, and according to the most recent 
data may affect between 26 and almost 38 million 
people worldwide [1, 2]. Future forecasts are 
even more alarming, in the United States alone, 
morbidity due to HF is projected to increase from 
current 5.7 million to almost 8 million by 2030 [3]. 
Despite continuous progress in pharmacotherapy 
[4, 5], widespread use of implantable cardioverter-
defibrillators (ICD) and resynchronization therapy, 
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all-cause mortality among patients with HF re-
mains high [6, 7]. Persons with significant left 
ventricular (LV) systolic dysfunction (LV ejection 
fraction [LVEF] < 40%) have the worst prognosis 
of all patients with HF [8], therefore, further evalu-
ation, risk stratification and new therapy options 
for these patients remains of important clinical 
value. Novel treatment methods, based on auto-
nomic nervous system (ANS) modulation [9–12], 
seem to be particularly promising in this context, 
as these treatments were shown to contribute to 
better quality of life and exercise capacity i.e., 
improvement of the New York Heart Association 
(NYHA) functional class and longer 6-minute walk-
ing distance. However, these beneficial effects 
were not associated with a decrease in all-cause 
mortality [9–14]. Possibly an appropriate selection 
of these patients, taking into account the initial 
ANS parameters that reveal the patients at the 
highest risk of all-cause mortality, could improve 
the results of these therapies. The majority of 
previous studies dealing with the ANS testing 
in HF constituted cardiovascular and arrhythmic 
mortality, and were conducted several years ago 
when both pharmacotherapy and electrotherapy 
differed substantially from those presently used 
[15–26]. The treatment of such individuals with HF 
has improved substantially over the last decades, 
and thus, the patient population at risk of death may 
have been altered as well. As a result, available data 
on high-risk patients with systolic dysfunction in 
the modern era are sparse and data from previous 
trials may no longer be applicable.
The aim of the present study was to verify 
whether simple, non-invasive autonomic parameters, 
such as baroreflex sensitivity (BRS) and short-term 
heart rate variability (HRV), could be valuable predic-
tors of all-cause mortality in patients with significant 
LV systolic dysfunction, and to identify the most ac-
curate cut-off values for these parameters.
Methods
Patient selection
In this prospective study, 205 patients with 
reduced LVEF (≤ 40%) were enrolled between 
October 2009 and June 2014. The protocol of the 
study was approved by the local Ethics Com-
mittee at the Medical University of Gdansk, and 
written informed consent was obtained from all 
participants. Additional inclusion criteria: sinus 
rhythm, optimal pharmacological therapy, stable 
clinical condition for at least 3 months before 
enrollment, and without significant features of 
hypervolemia at the moment of enrollment. The 
patients were excluded if they were younger than 
18 years old  had: a history of sustained ventricular 
arrhythmia (ventricular tachycardia or ventricular 
fibrillation) or cardiac arrest, NYHA functional 
class IV, permanent atrial fibrillation/flutter, per-
manent second- or third-degree atrioventricular 
block, implanted pacemaker, clinical features of 
coronary instability at the moment of enrolment, 
a revascularization (coronary angioplasty or/and 
surgery by-pass) within 3 months prior to the 
study, or incomplete coronary revascularization 
status (scheduled control coronarography, coronary 
angioplasty or surgery by-pass), clinical evidence 
of autonomic neuropathy, concomitant terminal 
disease and non-cardiologic comorbidities with 
a potentially unfavorable effect on survival.
ANS parameters
Autonomic nervous system tests were per-
formed according to the protocol precisely de-
scribed in our previous studies [27, 28] with the 
use of Mingograf 720C for ECG and Finapres 2300 
(Ohmeda) for beat-to-beat non-invasive arterial 
blood pressure, which was recorded continuously 
for 8 min, but in comparison to abovementioned 
studies [27, 28] during breathing with a controlled 
interval (0.25 Hz). Data received were converted 
from analog to digital signals, processed with dedi-
cated software [29] and analyzed according to the 
protocol [15, 30]. BRS (ms/mmHg) was computed 
by spectral analysis exactly as it was previously 
described [27, 28]. Furthermore, routine HRV 
indices: low-frequency (LF) to high-frequency 
(HF) ratio (LF/HF), relative spectral powers in LF 
(LFnu expressed in normalized units), as well as 
time-domain HRV parameters (standard deviation of 
normal-to-normal RR intervals [SDNN], the square 
root of the mean of squared differences between 
successive intervals [RMSSD], and the percent-
age of adjacent RR intervals differing by more than 
50 ms [pNN50]) were analyzed [16].
Follow-up
All patients were followed-up at the univer-
sity outpatient clinic with the first visit scheduled 
within 3 months of enrolment; the patients were 
checked every 6 months thereafter, or earlier 
if clinically required. During each visit, patient 
clinical status was evaluated and all adverse events 
were recorded, if any. The primary endpoint of the 
study was death of any cause. All deaths were veri-
fied against medical documentation of the patient 
and/or death certificate information.
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Statistical analysis
The variables were expressed as medians 
(Q25–Q75 intervals), or numbers (n) and percent-
ages (%). Comparisons between dead and living 
patients were made by the U Mann-Whitney test, 
the c2 test or the Yates c2 test. The accuracy of 
analyzed parameters as potential predictors of the 
study end-point was determined by area (AUC) 
under the receiver-operating characteristic (ROC) 
curve. An association between analyzed param-
eters and the end-point was assessed using the 
Cox hazard models, after the dichotomization of 
the measurements according to their cut-off values 
that maximized the hazard ratio (HR). For this pur-
pose, HR for progressively increasing appropriate 
values were comprised between the 20th and 50th 
percentiles (to have an adequate number of patients 
in each subgroup) was calculated and the point at 
which HR attained its maximum was identified. The 
time course of the end-point, stratified according to 
the aforementioned cut-off values, was estimated 
using the Kaplan-Meier method, and the associa-
tion between compared groups was estimated by 
the log-rank test. All results were considered 
statistically significant at p ≤ 0.05. The statistical 
analysis was conducted with R 2.15.2 environment. 
Results
Demographic, clinical and autonomic data of 
the group studied is presented in Table 1. Patients 
were approximately 63 years old, most patients had 
coronary artery disease and were in NYHA II class. 
Those with an ICD (including devices with cardiac 
resynchronization function) were approximately 
70% of the patients. 29 (14%) patients had LVEF 
> 35%, and 36 (17%) patients were in NYHA I 
class. Pharmacotherapy in both groups did not dif-
fer statistically. The average follow-up period was 
28 ± 9 months, during which 28 (14%) patients 
died, and they were characterized by significantly 
lower LVEF, more often presented with NYHA 
class III and digoxin use and less had an ICD im-
plantation. SDNN, LFnu, LF/HF and BRS were 
significantly lower in patients who died in com-
parison to other, living patients.
Predictors of all-cause mortality
Baroreflex sensitivity was the best predictor 
of all-cause mortality in the studied patients (AUC 
72.0% [95% CI 61.2–82.2]), whereas other auto-
nomic parameters and LVEF had lower discrimi-
natory powers: AUC 67.5 [95% CI 56.8–78.2] for 
SDNN, AUC 68.8% [95% CI 60.7–76.9] for LFnu, 
AUC 69.0 [95% CI 60.8–77.1] for LF/HF and AUC 
67.9% [95% CI 56.8–79.1] for LVEF. The Cox-
hazard regression analyses revealed that cut-off 
values maximally identifying patients at increased 
risk of death were 3.0 ms/mmHg for BRS, 41 for 
LFnu, 0.7 for LF/HF, 25 ms for SDNN and 25% for 
LVEF. All these values, as well as NYHA class III, 
were significantly associated with the incidence of 
the end-point in univariate Cox analyses (Fig. 1). 
The absence of ICD implantation was also 
a strong indicator risk of death (HR 3.21 [95% CI 
1.53–6.75], p < 0.002). Accuracy of the above-
mentioned cut-off values of BRS, LFnu, LF/HF, 
SDNN and LVEF in predicting the risk of death 
is presented in Table 2 — it was noted BRS ≤ 3.0 
ms/mmHg had the highest power in prediction 
of all-cause mortality in the patients studied. No 
other parameters from Table 1 were significant in 
predicting all-cause mortality in the Cox hazard 
regression analyses.
Kaplan-Meier curves illustrate the probability 
of all-cause mortality after dichotomization accord-
ing to cut-off values BRS (Fig. 2), SDNN (Fig. 3), 
LFnu (Fig. 4) and LF/HF (Fig. 5). 
Due to a relatively small number of end-points, 
the maximum number of predictors that could be 
used in a multivariate model without the risk of its 
overfitting was 2. Therefore, bivariate combinations 
of LVEF, NYHA III and ICD presence with above-
mentioned cut-off values for analyzed autonomic 
parameters were checked: BRS, SDNN, LFnu, and 
LF/HF turned-out to be independent significant 
predictors of the all-cause mortality (Table 3).
Discussion
The observation that decreased values of BRS, 
SDNN, LFnu and LF/HF are accurate predictors of 
all-cause mortality in clinically stable patients with 
reduced LVEF, even after adjusting for other well-
known clinical parameters (such as LVEF, NYHA 
class, ICD implantation) is the principal finding of the 
present study. The cut-off values determined in this 
study (BRS ≤ 3.0 ms/mmHg, SDNN ≤ 25 ms, LFnu 
≤ 41 and LF/HF ≤ 0.7) accurately identified patients 
who were at increased risk of all-cause mortality dur-
ing an average 2-year follow-up period. The novelty of 
the present study can be found in the demonstration 
that in the group of HF patients treated according to 
the current guidelines, in the era of widespread use 
of electrotherapy with ICD, the simple, non-invasive 
autonomic indices obtained from short-term systolic 
arterial pressure and electrocardiography signals are 
still accurate predictors of all-cause mortality.
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In two recent studies [27, 28], the usefulness 
of BRS and short-term HRV in prognosis, an in-
creased risk of hospitalization due to HF decom-
pensation [27], and identification of low-arrhythmic 
risk patients [28] was discovered. It needs to be 
noted, that cut-off values for BRS established in 
the abovementioned [27, 28], and other studies 
[15, 16, 31–33], are similar, at well-known 3.0 ms/ 
/mmHg cut-off on BRS estimates, which presents, 
according to Gouveia et al. [32], a natural partition 
of HF patients at risk.
Noticeably, the present study showed that 
BRS and short-term HRV were independent 
risk factors of death regardless of LVEF and 
Table 1. Clinical and demographic characteristics of the studied patients.
All  
(n = 205)
Dead patients  
(n = 28)
Alive patients  
(n = 177)
P*
Age [years] 63 (57–71) 64 (56–71) 61 (57–71) 0.442
Male 175 (85%) 25 (89%) 150 (85%) 0.771
CAD history 128 (62%) 16 (57%) 112 (63%) 0.532
Revascularization 129 (63%) 17 (61%) 113 (64%) 0.843
LVEF [%] 30 (25–35) 25 (20–33) 30 (25–35) < 0.032
QRS ≥ 120 ms 130 (63%) 18 (64%) 112 (63%) 1.000
NYHA class: < 0.041
I 36 (17%) 2 (7%) 34 (19%)
II 130 (63%) 16 (57%) 114 (64%)
III 39 (19%) 10 (36%) 29 (16%)
Beta-adrenolytics 197 (96%) 28 (100%) 169 (95%) 0.602
ACEI, ARB 193 (94%) 26 (93%) 167 (94%) 0.668
Spironolactone, eplerenone 115 (56%) 16 (57%) 99 (56%) 1.000
Antiplatelet therapy 159 (78%) 22 (79%) 137 (78%) 1.000
Amiodarone 21 (10%) 4 (14%) 17 (10%) 0.502
Statins 163 (80%) 20 (71%) 143 (81%) 0.309
Digoxin 11 (5%) 4 (14%) 7 (4%) < 0.047
Diuretics 110 (54%) 20 (71%) 90 (51%) 0.072
Arterial hypertension 120 (59%) 11 (39%) 109 (62%) < 0.038
Diabetes 51 (25%) 6 (21%) 45 (25%) 0.821
Renal function 0.092
GFR > 60 mL/min/1.73 m2 154 (75%) 19 (68%) 135 (76%)
GFR 30–59 mL/min/1.73 m2 44 (21%) 6 (21%) 38 (21%)
GFR < 30 mL/min/1.73 m2 7 (3%) 3 (11%) 4 (2%)
Hypercholesterolemia 114 (56%) 15 (54%) 99 (56%) 0.836
ICD 145 (71%) 14 (50%) 131 (77%) < 0.012
Autonomic parameters
Mean HP [ms] 1040 (966–1133) 996 (929–1122) 1050 (969–1133) 0.071
SDNN [ms] 25.8 (16.6–36.5) 15.0 (12.2–24.4) 27.2 (18.2–38.0) < 0.012
RMSSD [ms] 21.0 (13.2–34.0) 16.9 (9.0–26.8) 21.3 (13.6–36.0) 0.063
pNN50 [%] 1.84 (0–11.58) 0.78 (0–5.24) 2.31 (0–13.38) 0.088
LFnu 32.15 (15.35–52.7) 17.95 (11.27 –28.6) 35.8 (17.88–57.5) < 0.009
LF/HF 0.48 (0.19–1.12) 0.22 (0.12–0.40) 0.58 (0.23–1.38) < 0.008
BRS [ms/mmHg] 3.89 (2.24–6.55) 2.28 (1.51–3) 4.66 (2.74–7.98) < 0.015
*P value for comparison between patients who died and alive patients. CAD — coronary artery disease; LVEF — left ventricular ejection frac-
tion; NYHA — New York Heart Association; ACEI — angiotensin converting enzyme inhibitors; ARB — angiotensin receptor blockers GFR 
— glomerular filtration rate; ICD — implantable cardioverter-defibrillator;  HP — heart period; SDNN — standard deviation of the average R-R 
intervals of the sinus rhythm; RMSSD — square root of the mean squared difference of successive R-R intervals; pNN50 — proportion of suc-
cessive R-R intervals that differ by more than 50 ms; LFnu — spectral power in low-frequency range expressed in normalized units; LF/HF — 
LF to HF ratio; BRS — baroreflex sensitivity
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NYHA class, and, even more importantly, ir-
respective of ICD use, which can be considered 
a particularly important and novel finding. In the 
light of current discussions in the literature on 
the validity of ICD implantation in all patients 
with LV systolic dysfunction [34, 35], as well 
as in light of new methods of treatment of HF 
patients based on ANS modulation, the analyses 
presented in this paper seem to be of particular 
clinical significance.
In comparison to two recent studies [27, 28], 
in the present paper, BRS and HRV estimation 
were performed during breathing with a controlled 
interval (0.25 Hz), which is well-known methodo-
logical modification allowing the exclusion of the 
breathing rate influences on spontaneous BRS and 
HRV parameters in HF patients [36, 37].
Limitations of the study
There are potential limitations in the present 
study. Firstly, this was a small, single-center study, 
Figure 1. The Cox hazard regression analysis for pre-specified cut-off values of analyzed parameters as predictors of 
all-cause mortality during follow-up period; CI — confidence interval; LVEF — left ventricular ejection fraction; NYHA 
— New York Heart Association functional class; LFnu — spectral power in low-frequency range expressed in normal-
ized units; LF/HF — low-frequency to high-frequency ratio; SDNN — standard deviation of average R-R intervals of 
sinus rhythm; BRS — baroreflex sensitivity.
Table 2. Prognostic accuracy of the cut-off values of BRS, LFnu, LF/HF, SDNN, LVEF and NYHA III as 
predictors of death.
Parameters AUC (%) Characteristics (%)
(95% CI)
Predictive value (%)
(95% CI)
Sensitivity Specificity Positive Negative
LVEF ≤ 25% 62.4 53.57 71.19 22.73 90.65
(35.81–70.47) (64.12–77.35) (14.29–34.17) (84.66–94.45)
NYHA III 60.0 47.71 83.62 25.64 89.16
(20.71–54.17) (77.46–88.34) (14.57–41.08) (83.51–93.03)
BRS ≤ 3.0 ms/mmHg 72.0 76.19 67.80 29.63 94.12
(54.91–89.37) (58.92–75.55) (19.14–42.83) (86.96–97.46)
SDNN ≤ 25 ms 67.5 75.00 60.00 23.81 93.51
(53.13–88.81) (51.06–68.32) (14.99–35.64) (85.68–97.19)
LFnu ≤ 41 68.8 90.00 47.50 22.22 96.61
(69.90–97.21) (38.78–56.37) (14.54–32.42) (88.46–99.07)
LF/HF ≤ 0.7 69.0 90.00 47.90 22.50 96.61
(69.90–97.21) (39.13–56.80) (14.73–32.79) (88.46–99.07)
AUC — area under the receiver-operating characteristic (ROC) curve; CI — confidence interval; LVEF — left ventricular ejection fraction; NYHA 
— New York Heart Association functional class; BRS — baroreflex sensitivity; SDNN — standard deviation of the average R-R intervals of the 
sinus rhythm; LFnu — spectral power in low-frequency range expressed in normalized units; LF/HF — low-frequency to high-frequency ratio
0.0 0.6 1.2 1.8 2.4 3.0
EVENT
3.6 4.2 4.8 5.4
Hazard ratio 95% CI P
LVEF [%]
LVEF ≤ 25%
NYHA III
LFnu
LFnu ≤ 41
LF/HF
LF/HF ≤ 0.7
SDNN [ms]
SDNN ≤ 25 ms
BRS [ms/mmHg]
BRS ≤ 3.0 ms/mmHg
0.93
0.36
2.40
0.96
0.15
0.22
0.15
0.95
0.25
0.72
0.19
< 0.007
< 0.007
< 0.027
< 0.004
< 0.012
< 0.021
< 0.012
< 0.022
< 0.008
< 0.005
< 0.001
0.89–0.98
0.17–0.75
1.11–5.21
0.94–0.99
0.04–0.67
0.06–0.80
0.04–0.66
0.91–0.99
0.09–0.70
0.57–0.91
0.07–0.51
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Figure 2. Kaplan-Meier curves illustrating the probability of the EVENT during the follow-up period depending on pre-
specified cut-off values for baroreflex sensitivity (BRS).
Figure 3. Kaplan-Meier curves illustrating the probability of the EVENT during follow-up period depending on pre-
specified cut-off values for standard deviation of the average R-R intervals of the sinus rhythm (SDNN).
Figure 4. Kaplan-Meier curves illustrating the probability of the EVENT during follow-up period depending on pre-
specified cut-off values for spectral power in low-frequency range expressed in normalized units (LFnu).
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with a relatively short follow-up period; the results 
need to be confirmed in a larger group of patients 
with a longer observation periods. Secondly, some 
patients, apart from the fact that they were clinical-
ly stable, were not optimally treated concerning the 
three groups of drugs (ACEI/ARB, BB and MRA): 
some of them due to the significant contraindica-
tions or intolerance symptoms, another reason 
could be connected with the period of enrollment, 
which took place a few years ago and since then 
there has been further progress in pharmacologi-
cal treatment of patients with HF. Additionally, the 
authors did not analyse the influence of diuretics 
doses on mortality. The next limitation concerns 
BRS and HRV indices, which were not possible 
to measure in the patients with permanent atrial 
fibrillation/flutter, permanent second- or third-
degree atrioventricular block, and persons with 
paced rhythm; these patients are at the high risk of 
death, therefore further investigations concerning 
the prognosis of all-cause mortality amongst all 
HF patients with reduced LVEF are still needed. 
Figure 5. Kaplan-Meier curves illustrating the probability of the EVENT during follow-up period depending on pre-
specified cut-off values for low-frequency to high-frequency ratio (LF/HF).
Table 3. Bivariate Cox models for EVENTs for BRS and HRV indexes during follow-up period (adjusted 
to LVEF, NYHA III, or presence of ICD).
Hazard ratio 95% CI P
LVEF-adjusted HR for BRS ≤ 3.0 ms/mmHg 6.52 2.36–17.96 < 0.0001
LVEF-adjusted HR for SDNN ≤ 25 ms 3.68 1.32–10.25 < 0.013
LVEF-adjusted HR for LF/HF ≤ 0.7 6.18 1.43–26.73 < 0.015
LVEF-adjusted HR for LFnu ≤ 41 6.12 1.42–26.50 < 0.015
NYHA III-adjusted HR for BRS ≤ 3.0 ms/mmHg 5.24 1.92–14.36 < 0.001
NYHA III-adjusted HR for SDNN ≤ 25 ms 3.77 1.37–10.40 < 0.010
NYHA III-adjusted HR for LF/HF ≤ 0.7 5.67 1.29–24.81 < 0.021
NYHA III-adjusted HR for LFnu ≤ 41 5.61 1.28–24.57 < 0.022
ICD-adjusted HR for BRS ≤ 3.0 ms/mmHg 5.48 2.01–14.99 < 0.0001
ICD-adjusted HR for SDNN ≤ 25 ms 3.88 1.41–10.70 < 0.009
ICD-adjusted HR for LF/HF ≤ 0.7 6.56 1.52–28.33 < 0.012
ICD-adjusted HR for LFnu ≤ 41 6.52 1.51–28.15 < 0.012
CI — confidence interval; LVEF — left ventricular ejection fraction; BRS — baroreflex sensitivity; SDNN — standard deviation of the average 
R-R intervals of sinus rhythm; LFnu — relative spectral power in LF range, expressed in normalized units; LF/HF — low-frequency to high-
frequency ratio; NYHA — New York Heart Association functional class; ICD — implantable cardioverter-defibrillator
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Conclusions
The results of the present study suggest that 
simple, non-invasively obtained parameters of ANS 
activity, such as BRS and short-term HRV (SDNN, 
LFnu and LF/HF), remains helpful in the identifi-
cation of persons with increased risk of all-cause 
mortality amongst clinically stable patients with 
LV systolic dysfunction treated in line to current 
guidelines, even after adjusting for other basic 
clinical parameters, such as LVEF, NYHA class, 
and ICD implantation. 
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